Nothing Special   »   [go: up one dir, main page]

EA199900287A1 - Тиенотриазолодиазепиновые соединения и их фармацевтическое применение - Google Patents

Тиенотриазолодиазепиновые соединения и их фармацевтическое применение

Info

Publication number
EA199900287A1
EA199900287A1 EA199900287A EA199900287A EA199900287A1 EA 199900287 A1 EA199900287 A1 EA 199900287A1 EA 199900287 A EA199900287 A EA 199900287A EA 199900287 A EA199900287 A EA 199900287A EA 199900287 A1 EA199900287 A1 EA 199900287A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compound
inventive compound
useful
pharmaceutically acceptable
compounds
Prior art date
Application number
EA199900287A
Other languages
English (en)
Other versions
EA001732B1 (ru
Inventor
Хироюки Суеока
Хироцугу Комацу
Харухито Кобаяси
Сюдзи Ехара
Original Assignee
Еситоми, Фармасьютикал Индастриз, Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Еситоми, Фармасьютикал Индастриз, Лтд. filed Critical Еситоми, Фармасьютикал Индастриз, Лтд.
Publication of EA199900287A1 publication Critical patent/EA199900287A1/ru
Publication of EA001732B1 publication Critical patent/EA001732B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Тиенотриазолодиазепиновые соединения формулы (1)где каждый символ является таким, как определено в описании, их фармацевтически приемлемые соли или их гидраты и фармацевтические агенты, содержащие это соединение, его фармацевтически приемлемую соль или его гидрат. Фармацевтический агент, содержащий соединение по изобретению, полезен в качестве терапевтического агента, профилактического лекарственного средства или рецидивного лекарственного средства при воспалительных заболеваниях кишечника, вызываемых клеточной адгезией, таких как язвенный колит и болезнь Крона. Кроме того, соединение по изобретению может использоваться для профилактики и лечения венозной недостаточности и венозных язв или для поддержания ремиссии обоих заболеваний. Более того, вследствие низкой токсичности соединения по изобретению, что было установлено в экспериментах на животных, соединение полезно в качестве высоко безопасного фармацевтического продукта.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA199900287A 1996-09-13 1997-08-11 Тиенотриазолодиазепиновые соединения и лекарственное средство EA001732B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP24379396 1996-09-13
PCT/JP1997/002817 WO1998011111A1 (fr) 1996-09-13 1997-08-11 Composes de thienotriazolodiazepine et leurs utilisations a des fins medicinales

Publications (2)

Publication Number Publication Date
EA199900287A1 true EA199900287A1 (ru) 1999-08-26
EA001732B1 EA001732B1 (ru) 2001-08-27

Family

ID=17109041

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199900287A EA001732B1 (ru) 1996-09-13 1997-08-11 Тиенотриазолодиазепиновые соединения и лекарственное средство

Country Status (15)

Country Link
EP (1) EP0989131B1 (ru)
JP (1) JP3094453B2 (ru)
KR (1) KR100338144B1 (ru)
CN (1) CN1109037C (ru)
AT (1) ATE227727T1 (ru)
AU (1) AU716490B2 (ru)
CA (1) CA2265645C (ru)
DE (1) DE69717160T2 (ru)
DK (1) DK0989131T3 (ru)
EA (1) EA001732B1 (ru)
ES (1) ES2182108T3 (ru)
HK (1) HK1023571A1 (ru)
NO (1) NO323892B1 (ru)
PT (1) PT989131E (ru)
WO (1) WO1998011111A1 (ru)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001264303A1 (en) * 2000-06-16 2001-12-24 Mitsubishi Pharma Corporation Compositions controlling release ph range and/or speed
US8044042B2 (en) 2005-05-30 2011-10-25 Mitsubishi Tanabe Pharma Corporation Thienotriazolodiazepine compound and medicinal use thereof
EP2239264A4 (en) * 2007-12-28 2012-01-11 Mitsubishi Tanabe Pharma Corp ANTITUMOR AGENT
RS54592B1 (en) 2009-11-05 2016-08-31 Glaxosmithkline Llc BENZODIAZEPINE BROMODOMEN INHIBITOR
MX341212B (es) 2009-11-05 2016-08-11 Glaxosmithkline Llc * Inhibidor de bromodominio de benzodiazepina.
GB0919432D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
DK2571503T3 (en) 2010-05-14 2015-04-20 Dana Farber Cancer Inst Inc COMPOSITIONS AND THEIR USE IN THE TREATMENT OF NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS
US9301962B2 (en) 2010-05-14 2016-04-05 Baylor College Of Medicine Male contraceptive compositions and methods of use
CN103154246B (zh) 2010-05-14 2015-11-25 达那-法伯癌症研究所 用于治疗白血病的组合物和方法
JP5844358B2 (ja) 2010-06-22 2016-01-13 グラクソスミスクライン エルエルシー ベンゾトリアゾロジアゼピン化合物を含むブロモドメイン阻害剤
GB201020015D0 (en) * 2010-11-25 2011-01-12 Glaxo Group Ltd Method of treatment
AR084070A1 (es) * 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
WO2012075456A1 (en) 2010-12-02 2012-06-07 Constellation Pharmaceuticals Bromodomain inhibitors and uses thereof
US9422292B2 (en) 2011-05-04 2016-08-23 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
WO2012174487A2 (en) 2011-06-17 2012-12-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
DE102011082013A1 (de) * 2011-09-01 2013-03-07 Bayer Pharma AG 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
JP5989229B2 (ja) 2012-04-20 2016-09-07 アッヴィ・インコーポレイテッド イソインドロン誘導体
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
WO2013184878A1 (en) 2012-06-06 2013-12-12 Constellation Pharmaceuticals, Inc. Benzo [b] isoxazoloazepine bromodomain inhibitors and uses thereof
MX2014015156A (es) 2012-06-12 2015-08-06 Abbvie Inc Derivados de piridinona y piridazinona.
US20140018353A1 (en) * 2012-06-25 2014-01-16 Oncoethix Sa Method of treating b-cell malignant cancers and t-cell malignant cancers using thienotriazolodiazepine compounds
CA2881996A1 (en) 2012-08-16 2014-02-20 Bayer Pharma Aktiengesellschaft 2,3-benzodiazepines
JP6276277B2 (ja) 2012-09-28 2018-02-07 バイエル ファーマ アクチエンゲゼルシャフト Ｂｅｔタンパク質阻害性の５−アリールトリアゾロアゼピン
JP2015531365A (ja) * 2012-09-28 2015-11-02 オンコエシックス エスエー チエノトリアゾロジアゼピン化合物を含む医薬製剤
CN105377851B (zh) 2013-03-11 2018-07-20 密执安州立大学董事会 Bet布罗莫结构域抑制剂和使用这些抑制剂的治疗方法
US9714946B2 (en) 2013-03-14 2017-07-25 Dana-Farber Cancer Institute, Inc. Bromodomain binding reagents and uses thereof
EP3024327B1 (en) 2013-07-25 2019-09-04 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
JP6453877B2 (ja) * 2013-08-01 2019-01-16 オンコエシックス ゲーエムベーハー チエノトリアゾロジアゼピン化合物を含む医薬製剤
CN103694253A (zh) * 2013-11-04 2014-04-02 湖南华腾制药有限公司 一种噻吩并三唑并[4,3-a][1,4]二氮杂卓类化合物的制备方法
MX2016005980A (es) 2013-11-08 2016-12-09 Dana Farber Cancer Inst Inc Terapia de combinación para el cáncer usando inhibidores de la proteína bromodominio y extra-terminal.
JP2017504653A (ja) 2014-01-31 2017-02-09 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ジアミノピリミジンベンゼンスルホン誘導体およびその使用
CA2936256A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Diazepane derivatives and uses thereof
WO2015117087A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
AU2015222805B2 (en) 2014-02-28 2020-05-21 Tensha Therapeutics, Inc. Treatment of conditions associated with hyperinsulinaemia
WO2015131005A1 (en) 2014-02-28 2015-09-03 The Regents Of The University Of Michigan 9h-pyrimido[4,5-b]indoles and related analogs as bet bromodomain inhibitors
RS58730B1 (sr) 2014-06-20 2019-06-28 Constellation Pharmaceuticals Inc Kristalni oblici 2-((4s)-6-(4-hlorofenil)-1-metil-4h-benzo[c]izoksazolo[4,5-e]azepin-4-il)acetamida
MX2017001757A (es) 2014-08-08 2017-05-30 Dana Farber Cancer Inst Inc Derivados de dihidropteridinona y sus usos.
EP3177626A4 (en) 2014-08-08 2017-12-27 Dana Farber Cancer Institute, Inc. Diazepane derivatives and uses thereof
EA033325B1 (ru) 2014-10-27 2019-09-30 Тэнша Терапеутикс, Инк. Ингибиторы бромодомена
EP3256470B1 (en) 2014-12-23 2023-07-26 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
US10307407B2 (en) 2015-02-27 2019-06-04 The Regents Of The University Of Michigan 9H-pyrimido [4,5-B] indoles as BET bromodomain inhibitors
US10683305B2 (en) 2015-04-27 2020-06-16 Concert Pharmaceuticals, Inc. Deuterated OTX-015
WO2016196065A1 (en) 2015-05-29 2016-12-08 Genentech, Inc. Methods and compositions for assessing responsiveness of cancers to bet inhibitors
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
JP2018526421A (ja) 2015-09-11 2018-09-13 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド シアノチエノトリアゾロジアゼピンおよびこれらの使用
AU2016319785C1 (en) 2015-09-11 2021-04-01 Dana-Farber Cancer Institute, Inc. Acetamide thienotriazolodiazepines and uses thereof
SG11201803210YA (en) 2015-11-25 2018-05-30 Dana Farber Cancer Inst Inc Bivalent bromodomain inhibitors and uses thereof
JP6967522B2 (ja) 2016-02-15 2021-11-17 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン Ｂｅｔブロモドメイン阻害剤としての融合１，４−オキサゼピンおよび関連類似体
UA123786C2 (uk) 2016-04-06 2021-06-02 Дзе Ріджентс Оф Дзе Юніверсіті Оф Мічіган Деструктори білка mdm2
US10759808B2 (en) 2016-04-06 2020-09-01 The Regents Of The University Of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
EP3442976B1 (en) 2016-04-12 2022-07-20 The Regents of The University of Michigan Bet protein degraders
RU2741808C2 (ru) 2016-04-15 2021-01-28 Эббви Инк. Ингибиторы бромодомена
EP3454856B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
EP3455219A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR THE DEGRADATION OF TARGET PROTEINS
CA3036841A1 (en) 2016-09-13 2018-03-22 The Regents Of The University Of Michigan Fused 1,4-diazepines as bet protein degraders
CA3036834A1 (en) 2016-09-13 2018-03-22 The Regents Of The University Of Michigan Fused 1,4-oxazepines as bet protein degraders
WO2018064589A1 (en) 2016-09-29 2018-04-05 Dana-Farber Cancer Institute, Inc. Targeted protein degradation using a mutant e3 ubiquitin ligase
BR112019008435A2 (pt) 2016-12-16 2019-07-09 Hoffmann La Roche processos para a preparação de um composto de fórmula, processo para a fabricação de um composto de fórmula, processos para a purificação de um composto de fórmula, composto e presente invenção
US11046709B2 (en) 2017-02-03 2021-06-29 The Regents Of The University Of Michigan Fused 1,4-diazepines as BET bromodomain inhibitors
CA3064845A1 (en) * 2017-05-31 2018-12-06 Ayumi Pharmaceutical Corporation 6h-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivatives
EP3641762A4 (en) 2017-06-20 2021-03-10 C4 Therapeutics, Inc. N / O BONDED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION
EP3679028A1 (en) 2017-09-04 2020-07-15 C4 Therapeutics, Inc. Dihydroquinolinones
EP3679026A1 (en) 2017-09-04 2020-07-15 C4 Therapeutics, Inc. Glutarimide
EP3679027A1 (en) 2017-09-04 2020-07-15 C4 Therapeutics, Inc. Dihydrobenzimidazolones
US11267822B2 (en) 2017-09-13 2022-03-08 The Regents Of The University Of Michigan BET bromodomain protein degraders with cleavable linkers
EP3710002A4 (en) 2017-11-16 2021-07-07 C4 Therapeutics, Inc. DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION
WO2019191112A1 (en) 2018-03-26 2019-10-03 C4 Therapeutics, Inc. Cereblon binders for the degradation of ikaros
WO2019204354A1 (en) 2018-04-16 2019-10-24 C4 Therapeutics, Inc. Spirocyclic compounds
CN112312916A (zh) 2018-06-13 2021-02-02 戴布里股份公司 缩合三氮杂卓衍生物的制备及其作为bet抑制剂的用途
US11542273B2 (en) 2018-07-04 2023-01-03 Mitsubishi Tanabe Pharma Corporation Amide compound having bet proteolysis-inducing action and medicinal application thereof
CN113631559B (zh) * 2019-03-07 2023-05-23 南京明德新药研发有限公司 同时具有BET Bromodomain蛋白抑制和PD-L1基因调控作用的化合物
MX2022009700A (es) 2020-02-06 2022-09-07 Mitsubishi Tanabe Pharma Corp Compuesto de sulfonamida o sulfinamida que tiene el efecto de inducir la degradacion de la proteina de bromodominio 4 (brd4) y el uso farmaceutico del mismo.
WO2022048685A1 (zh) * 2020-09-07 2022-03-10 南京明德新药研发有限公司 苯并四氢呋喃肟类化合物的晶型及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA87377B (en) * 1986-01-21 1988-09-28 Boehringer Ingelheim Int New thieno-1,4-diazepine
EP0368175A1 (de) * 1988-11-06 1990-05-16 Boehringer Ingelheim Kg 3S,7S-3-(Morpholinocarbonyl)-5-(2-chlorphenyl)-7,10-dimethyl-3,4-dihydro-2H,7H-cyclopenta[4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin.
EP0387613A1 (de) * 1989-03-03 1990-09-19 Boehringer Ingelheim Kg Neue Thienodiazepine
EP0407955A1 (de) * 1989-07-12 1991-01-16 Boehringer Ingelheim Kg Neue Hetrazepine mit PAF-antagonistischer Wirkung, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO1994006801A1 (en) * 1990-05-23 1994-03-31 Yoshitomi Pharmaceutical Industries, Ltd. Thienodiazepine compound and medicinal use thereof
DE4027470A1 (de) * 1990-08-30 1992-03-05 Boehringer Ingelheim Kg Neue hetrazepinoide amide
EP0638560A4 (en) * 1991-10-11 1995-03-29 Yoshitomi Pharmaceutical MEDICINE FOR OSTEOPOROSIS AND DIAZEPINE COMPOUND *.
DE69230891T2 (de) * 1991-12-11 2000-10-05 Yoshitomi Pharmaceutical Industries, Ltd. Arzneimittel zur Behandlung von Autoimmunerkrankungen
JP3215489B2 (ja) * 1992-04-23 2001-10-09 日本電信電話株式会社 燃料電池排熱利用システムとその制御方法
EP0661284A1 (en) * 1992-09-18 1995-07-05 Yoshitomi Pharmaceutical Industries, Ltd. Thienodiazepine compound and medicinal use thereof
CA2159344A1 (en) * 1993-03-30 1994-10-13 Minoru Moriwaki Cell adhesion inhibitor and thienotriazolodiazepine compound
JP3633008B2 (ja) * 1993-11-15 2005-03-30 三菱ウェルファーマ株式会社 チエノトリアゾロジアゼピン化合物
JPH0879471A (ja) * 1994-09-01 1996-03-22 Konica Corp 画像形成装置

Also Published As

Publication number Publication date
PT989131E (pt) 2003-03-31
AU716490B2 (en) 2000-02-24
NO991191D0 (no) 1999-03-11
HK1023571A1 (en) 2000-09-15
DK0989131T3 (da) 2003-03-03
CN1237180A (zh) 1999-12-01
ES2182108T3 (es) 2003-03-01
EP0989131A1 (en) 2000-03-29
DE69717160D1 (de) 2002-12-19
NO991191L (no) 1999-04-23
KR20000036057A (ko) 2000-06-26
EP0989131B1 (en) 2002-11-13
ATE227727T1 (de) 2002-11-15
CN1109037C (zh) 2003-05-21
WO1998011111A1 (fr) 1998-03-19
EA001732B1 (ru) 2001-08-27
CA2265645C (en) 2007-01-23
CA2265645A1 (en) 1998-03-19
KR100338144B1 (ko) 2002-05-24
EP0989131A4 (en) 2000-03-29
DE69717160T2 (de) 2003-05-08
JP3094453B2 (ja) 2000-10-03
AU3786097A (en) 1998-04-02
NO323892B1 (no) 2007-07-16

Similar Documents

Publication Publication Date Title
EA199900287A1 (ru) Тиенотриазолодиазепиновые соединения и их фармацевтическое применение
NO171785C (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme kinazolinderivater
OA09334A (fr) "Dérivés d'acides aminés".
GR3023219T3 (en) Pyrazolopyridine compounds and processes for preparation thereof
IL154536A0 (en) Immunoregulatory compounds and derivatives and methods of treating diseases therewith
IL165181A0 (en) The use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases
DK0516941T3 (da) Pyrazolopyridinforbindelser og fremgangsmåder til fremstilling deraf
FI894693A0 (fi) Menetelmä valmistaa farmaseuttisesti arvokasta imidatsoliinijohdannaista
MA23639A1 (fr) Derives pyrrocarbazole, leur preparation, les compositions pharmaceutiques les contenant, leur utilisation dans le traitement des tumeurs malignes.
DK0570294T3 (da) 2-formylpyridinthiosemicarbazonderivater, deres fremstilling og deres anvendelse som antitumormiddel
NO923200L (no) Piperidin-derivater
NO905620D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive kinazolin-derivater.
ES2068216T3 (es) Compuestos de tienotriazolodiazepina y usos farmaceuticos de los mismos.
KR970703147A (ko) 동맥경화 억제제(Arteriosclerosis Depressant)
DK451687A (da) 2-guanidino-4-arylthiazol-forbindelser og farmaceutiske praeparater indeholdende disse
ATE38982T1 (de) Guanidinmethylcyclohexancarbonsaeure-derivate, verfahren zur herstellung und pharmazeutische mittel.
ATE109003T1 (de) Therapeutisches mittel gegen pollakiurie, harndrang oder harninkontinenz, das alpha-phenyl- alpha-pyridylalkan-carbonsäurederivate enthält.
EP0272849A3 (en) Use of 2-oxo-imidazolidine derivatives in the treatment of kidney diseases
GR3030952T3 (en) Salmycins, a process for their preparation and their use as a pharmaceutical.
ZA882775B (en) Pharmaceutical use of organic compounds
TH13247EX (th) อนุพันธ์เททราไฮโดรฟิร์โรโล [1,2-a]ไพราชีน-4-สไพโร-3'-พิริโรลิดีน กรรมวิธีสำหรับเตรียมสารนั้นและสารผสมในทางเภสัชกรรมซึ่งมีสารนั้น
IT1107771B (it) Composizione farmaceutica antiartritica ed antiinfiammatoria
TH31635A (th) อนุพันธ์คาร์โบไฮเดรต

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

TC4A Change in name of a patent proprietor in a eurasian patent

Designated state(s): AM AZ BY KZ KG MD TJ TM

PD4A Registration of transfer of a eurasian patent in accordance with the succession in title
TC4A Change in name of a patent proprietor in a eurasian patent
MK4A Patent expired

Designated state(s): RU